The Pros And Cons Of Single-Use Systems - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Pros And Cons Of Single-Use Systems

Pharmaceutical Technology Europe
Volume 22, Issue 10

This article is part of a special feature on single-use systems that was published in the October issue of PTE Digital, available at

Salavadi S. Easwaran
The willingness of the industry to use singleuse bioreactors is currently influenced by the criticality of the step, the value of the product and the time for product development and production.


Single-use bioreactors are considered safe, simple and clean, and the possibility of batchtobatch contamination by adventitious microorganisms or through product crosscontamination is significantly controlled. One of the biggest advantages of such systems, however, is flexibility. The increasing trend towards multidrug facilities demands the production of different drugs using the same facility, with minimum time and cost. In such situations, the main manufacturing bottleneck is line clearance and cleaning validation. Singleuse bioreactors almost completely eliminate these problems.

Additionally, single-use bioreactors provide maximum savings on the time spent to prepare the system for the next batch. As an example, a 2-h changeover time with a single-use bioreactor would equate to a changeover time of 6–10 h with a stainless steel bioreactor for the same product, and 3 weeks for a full product changeover.

Obstacles to adoption

There are also some key challenges associated with single-use bioreactors. In particular, such systems are noncustomisable (since customisation would defeat their key advantage of plug and play) and can provide challenges when it comes to scale up since the volume size is restricted (<2000 L). Disposal can also be a problem. In many cases, singleuse bioreactors are produced from plastic derivatives. In addition to validation concerns related to potential leachable and extractable materials, the largescale disposal of such plastic reactors on a regular basis is also an environmental concern. This is a key challenge, particularly in countries where the disposal of plastics is strictly controlled.

Future innovations

In the future, the most important future development in singleuse bioreactor technology will be the increase in capacity to match common largescale process capacities. Singleuse bioreactor customisation will also mark a significant innovation, whereby the bioreactor system will fit into the existing space without compromising process requirements.

Salavadi S. Easwaran is Technology Manager-PMT, at Merck Millipore, India.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here